(Q36323256)

13 August 2017

1 reference

title

Posaconazole: a broad-spectrum triazole antifungal (English)

1 reference

13 August 2017

author

Dimitrios P Kontoyiannis

4

object named as

Dimitrios P Kontoyiannis

1 reference

13 August 2017

Harrys A Torres

1

1 reference

13 August 2017

Ray Y Hachem

2

1 reference

13 August 2017

Roy F Chemaly

3

1 reference

13 August 2017

Issam I Raad

5

1 reference

13 August 2017

publication date

1 December 2005

1 reference

13 August 2017

number of pages

11

1 reference

Lancet Infectious Diseases

inferred from page(s)

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

775-785

1 reference

Aspergillosis. Pathogenesis, clinical manifestations, and therapy

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Invasive aspergillosis in 2002: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Fusarium infection in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Echinocandin antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Voriconazole: a new triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal drug resistance of pathogenic fungi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Emerging azole antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro susceptibilities of zygomycetes to conventional and new antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Azole cross-resistance in Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole: clinical pharmacology and potential for management of fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Risk of Fungemia Due to Rhodotorula and Antifungal Susceptibility Testing of Rhodotorula Isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro antifungal susceptibilities of Trichosporon species.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal therapy of murine Aspergillus terreus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Infections caused by Fusarium species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro and in vivo activities of posaconazole against Coccidioides immitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Treatment of murine fusariosis with SCH 56592

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Toward more effective antifungal therapy: the prospects of combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Interactions of posaconazole and flucytosine against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Disposition of posaconazole following single-dose oral administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Clinical pharmacology of antifungal compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Antifungal treatment in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

New agents for invasive mycoses in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Activity of posaconazole in the treatment of central nervous system fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole therapy for chronic refractory coccidioidomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Breakthrough Candida infections in patients receiving voriconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Management of systemic fungal infections: alternatives to itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

1 reference

7 January 2021

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Zygomycosis: reemergence of an old pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Zygomycosis in the 1990s in a tertiary-care cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Zygomycetes in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Sinus zygomycosis in a patient receiving voriconazole prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Endemic mycoses in a cancer hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

Refractory coccidioidomycosis treated with posaconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970297-8

7 January 2021

10.1016/S1473-3099(05)70297-8

Identifiers

DOI

1 reference

13 August 2017

1 reference